AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-inducedgastrointestinal toxicity
Authors: Suri, S Monkkonen, J Taskinen, M Pesonen, J Blank, MA Phipps, RJ Rogers, MJ
Citation: S. Suri et al., Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-inducedgastrointestinal toxicity, BONE, 29(4), 2001, pp. 336-343
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
Authors: Benford, HL McGowan, NWA Helfrich, MH Nuttall, ME Rogers, MJ
Citation: Hl. Benford et al., Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro, BONE, 28(5), 2001, pp. 465-473
The cellular uptake and metabolism of clodronate in RAW 264 macrophages
Authors: Monkkonen, H Rogers, MJ Makkonen, M Niva, S Auriola, S Monkkonen, J
Citation: H. Monkkonen et al., The cellular uptake and metabolism of clodronate in RAW 264 macrophages, PHARM RES, 18(11), 2001, pp. 1550-1555
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro nd inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
Authors: Dunford, JE Thompson, K Coxon, FP Luckman, SP Hahn, FM Poulter, CD Ebetino, FH Rogers, MJ
Citation: Je. Dunford et al., Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro nd inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J PHARM EXP, 296(2), 2001, pp. 235-242
The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate - Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis
Authors: Frith, JC Monkkonen, J Auriola, S Monkkonen, H Rogers, MJ
Citation: Jc. Frith et al., The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate - Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis, ARTH RHEUM, 44(9), 2001, pp. 2201-2210
Use of the kinetic equilibrium between aminoacyl-tRNA formation and hydrolysis in inhibition assays of aminoacyl-tRNA synthetase
Authors: Jordan, DB Abell, LM Picollelli, MA Senator, DR Mason, JL Rogers, MJ Rendina, AR
Citation: Db. Jordan et al., Use of the kinetic equilibrium between aminoacyl-tRNA formation and hydrolysis in inhibition assays of aminoacyl-tRNA synthetase, ANALYT BIOC, 298(1), 2001, pp. 133-136
Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry
Authors: Monkkonen, H Moilanen, P Monkkonen, J Frith, JC Rogers, MJ Auriola, S
Citation: H. Monkkonen et al., Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry, J CHROMAT B, 738(2), 2000, pp. 395-403
Statins: lower lipids and better bones?
Authors: Rogers, MJ
Citation: Mj. Rogers, Statins: lower lipids and better bones?, NAT MED, 6(1), 2000, pp. 21-23
Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
Authors: Coxon, FP Helfrich, MH Van't Hof, R Sebti, S Ralston, SH Hamilton, A Rogers, MJ
Citation: Fp. Coxon et al., Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298, J BONE MIN, 15(8), 2000, pp. 1467-1476
Bisphosphonates - Mechanisms of action in multiple myeloma
Authors: Shipman, CM Rogers, MJ Vanderkerken, K Van Camp, B Russell, RGG Croucher, PI
Citation: Cm. Shipman et al., Bisphosphonates - Mechanisms of action in multiple myeloma, ACTA ONCOL, 39(7), 2000, pp. 829-835
Effects of interruption of apicoplast function on malaria infection, development, and transmission
Authors: Sullivan, M Li, J Kumar, S Rogers, MJ McCutchan, TF
Citation: M. Sullivan et al., Effects of interruption of apicoplast function on malaria infection, development, and transmission, MOL BIOCH P, 109(1), 2000, pp. 17-23
Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis
Authors: Copeland, RA Marcinkeviciene, J Haque, TS Kopcho, LM Jiang, WJ Wang, K Ecret, LD Sizemore, C Amsler, KA Foster, L Tadesse, S Combs, AP Stern, AM Trainor, GL Slee, A Rogers, MJ Hobbs, F
Citation: Ra. Copeland et al., Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis, J BIOL CHEM, 275(43), 2000, pp. 33373-33378
The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma
Authors: Shipman, CM Vanderkerken, K Rogers, MJ Lippitt, JM Asosingh, K Hughes, DE Van Camp, B Russell, RGG Croucher, PI
Citation: Cm. Shipman et al., The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma, BR J HAEM, 111(1), 2000, pp. 283-286
Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones
Authors: Marcinkeviciene, J Rogers, MJ Kopcho, L Jiang, WJ Wang, K Murphy, DJ Lippy, J Link, S Chung, TDY Hobbs, F Haque, T Trainor, GL Slee, A Stern, AM Copeland, RA
Citation: J. Marcinkeviciene et al., Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones, BIOCH PHARM, 60(3), 2000, pp. 339-342
A second dihydroorotate dehydrogenase (type A) of the human pathogen Enterococcus faecalis: Expression, purification, and steady-state kinetic mechanism
Authors: Marcinkeviciene, J Jiang, WJ Locke, G Kopcho, LM Rogers, MJ Copeland, RA
Citation: J. Marcinkeviciene et al., A second dihydroorotate dehydrogenase (type A) of the human pathogen Enterococcus faecalis: Expression, purification, and steady-state kinetic mechanism, ARCH BIOCH, 377(1), 2000, pp. 178-186
Clinical pharmacology of bisphosphonates
Authors: Russell, RG Croucher, PJ Rogers, MJ
Citation: Rg. Russell et al., Clinical pharmacology of bisphosphonates, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 377-392
Bisphosphonates: From the laboratory to the clinic and back again
Authors: Russell, RGG Rogers, MJ
Citation: Rgg. Russell et Mj. Rogers, Bisphosphonates: From the laboratory to the clinic and back again, BONE, 25(1), 1999, pp. 97-106
Molecular mechanisms of action of bisphosphonates
Authors: Rogers, MJ Frith, JC Luckman, SP Coxon, FP Benford, HL Monkkonen, J Auriola, S Chilton, KM Russell, RGG
Citation: Mj. Rogers et al., Molecular mechanisms of action of bisphosphonates, BONE, 24(5), 1999, pp. 73S-79S
Effects of bisphosphonates on the inflammatory processes of activated macrophages
Authors: Monkkonen, J Makkonen, N Rogers, MJ Frith, JC Auriola, S
Citation: J. Monkkonen et al., Effects of bisphosphonates on the inflammatory processes of activated macrophages, PHOSPHOR SU, 146, 1999, pp. 321-324
Bisphosphonates: Pharmacology, mechanisms of action and clinical uses
Authors: Russell, RGG Croucher, PI Rogers, MJ
Citation: Rgg. Russell et al., Bisphosphonates: Pharmacology, mechanisms of action and clinical uses, OSTEOPOR IN, 9, 1999, pp. 66-80
Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite
Authors: Makkonen, N Salminen, A Rogers, MJ Frith, JC Urtti, A Azhayeva, E Monkkonen, J
Citation: N. Makkonen et al., Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite, EUR J PH SC, 8(2), 1999, pp. 109-118
The pharmacology of bisphosphonates and new insights into their mechanismsof action
Authors: Russell, RGG Rogers, MJ Frith, JC Luckman, SP Coxon, FP Benford, HL Croucher, PI Shipman, C Fleisch, HA
Citation: Rgg. Russell et al., The pharmacology of bisphosphonates and new insights into their mechanismsof action, J BONE MIN, 14, 1999, pp. 53-65
Comparison of effect of intracanal use of ketorolac tromethamine and dexamethasone with oral ibuprofen on post treatment endodontic pain
Authors: Rogers, MJ Johnson, BR Remeikis, NA BeGole, EA
Citation: Mj. Rogers et al., Comparison of effect of intracanal use of ketorolac tromethamine and dexamethasone with oral ibuprofen on post treatment endodontic pain, J ENDODONT, 25(5), 1999, pp. 381-384
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
Authors: Fisher, JE Rogers, MJ Halasy, JM Luckman, SP Hughes, DE Masarachia, PJ Wesolowski, G Russell, RGG Rodan, GA Reszka, AA
Citation: Je. Fisher et al., Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, P NAS US, 96(1), 1999, pp. 133-138
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes ofbisphosphonate drugs
Authors: Benford, HL Frith, JC Auriola, S Monkkonen, J Rogers, MJ
Citation: Hl. Benford et al., Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes ofbisphosphonate drugs, MOLEC PHARM, 56(1), 1999, pp. 131-140
Risultati: 1-25 | 26-28